NCT03907202 - A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

December 3, 2019

Study Completion Date

December 3, 2019

Conditions

Type II Diabetes Mellitus

Interventions

DRUG

Daily injection of KBP/placebo for up to 28 days

Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.

Trial Locations (1)

D-41460

Profil Institut für Stoffwechselforschung GmbH, Neuss